Literature DB >> 15734770

Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function.

Antonio Maria Leone1, Sergio Rutella, Giuseppina Bonanno, Antonio Abbate, Antonio G Rebuzzi, Silvia Giovannini, Mariaelena Lombardi, Leonarda Galiuto, Giovanna Liuzzo, Felicita Andreotti, Gaetano A Lanza, Anna Maria Contemi, Giuseppe Leone, Filippo Crea.   

Abstract

AIMS: Recent data suggest that the administration of bone marrow-derived stem cells (BMSC) might improve myocardial perfusion and left ventricular (LV) function after acute myocardial infarction (AMI). The aim of this study was to assess spontaneous mobilization of BMSC expressing the haematopoietic and endothelial progenitor cell-associated antigen CD34+ after AMI and its relation to post-infarction remodelling. METHODS AND
RESULTS: Peripheral blood concentration of CD34+ BMSC was measured by flow cytometry in 54 patients with AMI, 26 patients with chronic stable angina (CSA), and 43 normal healthy subjects. In patients with AMI, LV function was measured by 2D-echocardiography. Eighteen AMI patients were reassessed at 1 year. BMSC concentration was higher in patients with AMI (mean peak value: 7.04+/-6.27 cells/microL), than in patients with CSA (3.80+/-2.12 cells/microL, P=0.036) and in healthy controls (1.87+/-1.52 cells/microL, P<0.001). At multivariable analysis statin use (P<0.001), primary percutaneous intervention (P=0.048) and anterior AMI (P=0.05) were the only independent predictors of increased BMSC mobilization after AMI. In the 28 patients without subsequent acute coronary events reassessed at 1 year follow-up, CD34+ cell concentration was an independent predictor of global and regional improvement of LV function (r=0.52, P=0.004 and r=-0.41, P=0.03, respectively).
CONCLUSION: AMI is followed by enhanced spontaneous mobilization of BMSC, in particular, in patients on statin therapy and following a primary percutaneous intervention. More importantly persistent spontaneous mobilization of BMSC might contribute to determine a more favourable post-AMI remodelling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15734770     DOI: 10.1093/eurheartj/ehi164

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  65 in total

Review 1.  Resident vascular progenitor cells--diverse origins, phenotype, and function.

Authors:  Peter J Psaltis; Adriana Harbuzariu; Sinny Delacroix; Eric W Holroyd; Robert D Simari
Journal:  J Cardiovasc Transl Res       Date:  2010-11-30       Impact factor: 4.132

Review 2.  Lysophospholipids in coronary artery and chronic ischemic heart disease.

Authors:  Ahmed Abdel-Latif; Paula M Heron; Andrew J Morris; Susan S Smyth
Journal:  Curr Opin Lipidol       Date:  2015-10       Impact factor: 4.776

3.  Cell-based therapies after myocardial injury.

Authors:  Hüseyin Ince; Christof Stamm; Christoph A Nienaber
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12

4.  Safety of granulocyte-colony-stimulating factor in acute myocardial infarction (the Rigenera study).

Authors:  A M Leone; L Galiuto; S Rutella; M B Giannico; S Brugaletta; B Garramone; V De Stefano; G Liuzzo; M L Calcagni; F Cirillo; A Giordano; G Niccoli; L M Biasucci; A G Rebuzzi; G Leone; F Crea
Journal:  Heart       Date:  2006-12       Impact factor: 5.994

5.  Neuroprotective effect of bone marrow stromal cell combination with atorvastatin in rat model of spinal cord injury.

Authors:  Fang Li; Dan Fei; Libo Sun; Sixun Zhang; Yue Yuan; Li Zhang; Kuiming Zhao; Rui Li; Yanbing Yu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

6.  Delivery of progenitor cells with injectable shear-thinning hydrogel maintains geometry and normalizes strain to stabilize cardiac function after ischemia.

Authors:  Ann C Gaffey; Minna H Chen; Alen Trubelja; Chantel M Venkataraman; Carol W Chen; Jennifer J Chung; Susan Schultz; Chandra M Sehgal; Jason A Burdick; Pavan Atluri
Journal:  J Thorac Cardiovasc Surg       Date:  2018-11-14       Impact factor: 5.209

Review 7.  A comparison of stem cells for therapeutic use.

Authors:  Denis O Rodgerson; Alan G Harris
Journal:  Stem Cell Rev Rep       Date:  2011-11       Impact factor: 5.739

8.  Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response.

Authors:  Xiaoyin Wang; Junya Takagawa; Viola C Lam; Daniel J Haddad; Diana L Tobler; Pamela Y Mok; Yan Zhang; Brian T Clifford; Kranthi Pinnamaneni; Shereen A Saini; Robert Su; Maya J Bartel; Richard E Sievers; Larry Carbone; Scott Kogan; Yerem Yeghiazarians; Michelle Hermiston; Matthew L Springer
Journal:  Sci Transl Med       Date:  2011-09-14       Impact factor: 17.956

9.  Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats.

Authors:  G P Fadini; S Sartore; M Schiavon; M Albiero; I Baesso; A Cabrelle; C Agostini; A Avogaro
Journal:  Diabetologia       Date:  2006-10-27       Impact factor: 10.122

Review 10.  Intramyocardial fibroblast myocyte communication.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Circ Res       Date:  2010-01-08       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.